Myelodysplastic disorders (or myelodysplastic syndrome) are a group of acquired clonal disorders of the haemopoietic stem cell characterised by:
A single abnormal multipotential cell in the bone marrow is affected. These disorders were formerly grouped under the the term "preleukaemia" since they may transform into acute myeloid leukaemia, but this term is now used to describe any condition predisposing to leukaemia.
The majority of patients myelodysplastic syndrome present with fatigue due to anaemia, although it is not uncommon for the diagnosis to be made as a result of unexplained macrocytosis or cytopaenia
Approximately 2/3 of patients succumb to the disease within 3-4 years after presentation, and individuals with high-risk MDS generally survive about 1 year. Given that the disease is more prevalent in the elderly who often have comorbid conditions, the current treatment of MDS consists mainly of supportive care. Curative treatments are restricted to younger, healthy individuals with histocompatible (HLA)-matched donors for allogenic transplant or those able to undergo intensive chemotherapeutic regimens (2).
Notes:
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.